Compare Incyte Corporation (INCY) vs Teradyne, Inc. (TER) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Incyte Corporation vs Teradyne, Inc. — how do they compare? Incyte Corporation trades at $121.12 (market cap $24.54B), while Teradyne, Inc. trades at $403.7 (market cap $59.34B). The key difference: Teradyne, Inc. is far larger — about 2.4× Incyte Corporation's market cap, and Teradyne, Inc. pays a 0.14% dividend while Incyte Corporation pays none. Which is the better fit depends on your goals.
| INCY | TER | |
|---|---|---|
Market Cap | $24.54B | $59.34B |
Sector | Health | Technology |
52-Week High | $129.93 | $483.84 |
52-Week Low | $81.61 | $109.30 |
Enterprise Value | $20.04B | $59.09B |
Dividend Yield | — | 0.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INCY trades at $121.55, near its consensus price target of $122.82, with a bullish technical signal and strong recent earnings beats. Revenue grew to $5.14B in 2025, with net income surging to $1.29B, reflecting robust profitability. The company raised its 2026 revenue outlook following strong Q2 results and positive developments like EU approval for Opzelura.
Outlook is positive with solid fundamentals and analyst support, though risks include competitive pressures and reliance on key products. The stock offers growth potential but requires monitoring of execution and market conditions.
Teradyne (TER) trades at $365.10, down 3.75% on the day despite strong Q2 2026 earnings that beat expectations with EPS of $2.47 versus $2.09 forecast. The stock shows neutral technical signals with support at $358 and resistance at $380, while fundamentals remain robust with 25.77% net margins and 36.66% ROE. Recent news highlights AI-driven semiconductor test demand fueling record revenues.
Outlook remains positive with analyst consensus price target of $481.63 (32% upside) and no sell ratings. Key risks include premium valuation (P/E 52.14) and dependence on semiconductor cycle volatility. Strong institutional ownership and consistent earnings beats support bullish sentiment for long-term growth in AI and robotics markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Incyte Corporation
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.
Read more on INCY →About Teradyne, Inc.
Teradyne provides testing equipment, including automated test equipment for semiconductors, system testing for hard disk drives, circuit boards, and electronics systems and wireless testing for devices. The firm entered the industrial automation market in 2015, into which it sells collaborative and autonomous robots for factory applications. Teradyne serves numerous end markets and geographies directly and indirectly with its products, but its most significant exposure is to semiconductor testing, which made up 71% of 2021 sales. Teradyne serves vertically integrated, fabless, and foundry chipmakers with its equipment.
Read more on TER →
